Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for SPRY

Stock Name	Silverback Therapeutics Inc
Ticker	SPRY(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US82835W1080

Show aggregate SPRY holdings

News associated with SPRY

XTX Topco Ltd Grows Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): XTX Topco Ltd grew its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 54.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,647 shares of the company’s stock after buying an additional 17,429 shares during the period. XTX Topco Ltd’s holdings in […] - 2025-08-06 05:18:53
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Consensus PT from Brokerages: Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) have received a consensus rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year […] - 2025-07-14 02:56:47
Oppenheimer & Co. Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Oppenheimer & Co. Inc. purchased a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the 1st quarter, Holdings Channel reports. The firm purchased 15,014 shares of the company’s stock, valued at approximately $189,000. Other large investors have also modified their holdings of the company. Wellington Management Group LLP boosted its position in […] - 2025-07-04 04:36:46
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder Sells 740,149 Shares of Stock: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) major shareholder James E. Flynn sold 740,149 shares of the business’s stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $18.46, for a total value of $13,663,150.54. Following the completion of the transaction, the insider directly owned 4,887,254 shares […] - 2025-07-03 05:26:53
ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded to “Hold” at Wall Street Zen: Wall Street Zen upgraded shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning. A number of other brokerages have also recently commented on SPRY. Scotiabank initiated coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set […] - 2025-06-29 05:18:51
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target […] - 2025-06-19 02:46:58
Wellington Management Group LLP Buys 917 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Wellington Management Group LLP raised its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 0.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 163,252 shares of the company’s stock after purchasing an additional 917 shares during the period. Wellington Management Group LLP’s holdings in ARS Pharmaceuticals were worth $1,722,000 as of […] - 2025-06-06 06:12:51
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by Deutsche Bank AG: Deutsche Bank AG increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 50.8% in the fourth quarter, Holdings Channel reports. The firm owned 43,377 shares of the company’s stock after purchasing an additional 14,604 shares during the period. Deutsche Bank AG’s holdings in ARS Pharmaceuticals were worth $458,000 as of its most […] - 2025-05-30 04:46:50
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Northern Trust Corp: Northern Trust Corp lifted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 5.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 478,153 shares of the company’s stock after acquiring an additional 25,773 shares during the period. Northern Trust Corp’s holdings in ARS Pharmaceuticals were worth $5,045,000 as of […] - 2025-05-22 04:20:52
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Position Boosted by Wells Fargo & Company MN: Wells Fargo & Company MN lifted its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 47.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 41,701 shares of the company’s stock after acquiring an additional 13,361 shares during the quarter. Wells Fargo & Company MN’s holdings in ARS Pharmaceuticals were worth $440,000 […] - 2025-05-05 05:00:50
Brokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month […] - 2025-04-30 02:10:55
Raymond James Financial Inc. Takes $6.58 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Raymond James Financial Inc. purchased a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 623,281 shares of the company’s stock, valued at approximately $6,576,000. Other institutional investors have also made […] - 2025-04-24 06:31:08
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,002 Shares: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) Director Laura Shawver sold 50,002 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $12.30, for a total transaction of $615,024.60. Following the sale, the director now owns 210,346 shares of the company’s […] - 2025-04-10 05:12:56
Intech Investment Management LLC Has $322,000 Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Intech Investment Management LLC lifted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 85.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 30,545 shares of the company’s stock after buying an additional 14,051 shares during the quarter. Intech Investment […] - 2025-03-26 07:16:48
Raymond James Financial Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Raymond James Financial Inc. purchased a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the fourth quarter, HoldingsChannel reports. The fund purchased 623,281 shares of the company’s stock, valued at approximately $6,576,000. Other large investors also recently added to or reduced their stakes in the company. Compass Capital Corp MA ADV purchased […] - 2025-03-24 05:50:52
Scotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY): Scotiabank began coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) in a report released on Friday, MarketBeat.com reports. The firm issued a sector outperform rating and a $30.00 target price on the stock. SPRY has been the subject of several other research reports. Raymond James lifted their target price on ARS Pharmaceuticals from […] - 2025-03-10 03:50:50
Allspring Global Investments Holdings LLC Buys 165,950 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Allspring Global Investments Holdings LLC increased its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 93.1% during the 4th quarter, Holdings Channel reports. The fund owned 344,171 shares of the company’s stock after acquiring an additional 165,950 shares during the period. Allspring Global Investments Holdings LLC’s holdings in ARS Pharmaceuticals were […] - 2025-02-21 06:12:48

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc SPRY holdings

Date	Number of SPRY Shares Held	Base Market Value of SPRY Shares	Local Market Value of SPRY Shares	Change in SPRY Shares Held	Change in SPRY Base Value	Current Price per SPRY Share Held	Previous Price per SPRY Share Held
2025-09-26 (Friday)	3,620	USD 35,476	USD 35,476
2025-09-25 (Thursday)	3,620	USD 34,535	USD 34,535	0	USD -326	USD 9.54006	USD 9.63011
2025-09-24 (Wednesday)	3,620	USD 34,861	USD 34,861
2025-09-17 (Wednesday)	3,598	USD 34,433	USD 34,433	0	USD 576	USD 9.57004	USD 9.40995
2025-09-16 (Tuesday)	3,598	USD 33,857	USD 33,857
2025-09-12 (Friday)	3,576	USD 35,867	USD 35,867
2025-09-11 (Thursday)	3,576	USD 36,296	USD 36,296

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SPRY by Blackrock for IE00B3VWM098

Show aggregate share trades of SPRY

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-08-21 SELL -33 14.870* 14.13 Profit of 466 on sale
2025-07-31 BUY 99 17.680* 14.10
2025-06-30 SELL -66 17.450* 13.67 Profit of 902 on sale
2025-06-25 SELL -33 17.260* 13.58 Profit of 448 on sale
2025-06-20 SELL -66 15.800* 13.52 Profit of 892 on sale
2025-05-23 BUY 33 14.980* 13.32
2025-05-19 SELL -33 14.260* 13.28 Profit of 438 on sale
2025-05-15 SELL -99 12.195* 13.29 Profit of 1,316 on sale
2025-05-12 SELL -33 13.290* 13.30 Profit of 439 on sale
2025-05-09 SELL -33 13.440* 13.30 Profit of 439 on sale
2025-04-30 SELL -33 13.970* 13.25 Profit of 437 on sale
2025-04-24 SELL -66 14.640* 13.22 Profit of 872 on sale
2025-04-17 SELL -33 14.880* 13.14 Profit of 434 on sale
2025-04-15 SELL -99 14.990* 13.10 Profit of 1,297 on sale
2025-04-14 SELL -99 14.470* 13.09 Profit of 1,296 on sale
2025-04-09 SELL -132 13.340* 13.07 Profit of 1,725 on sale
2025-04-07 SELL -231 12.830* 13.08 Profit of 3,022 on sale
2025-04-04 SELL -330 12.800* 13.09 Profit of 4,318 on sale
2025-03-31 BUY 33 12.580* 13.10
2025-03-19 SELL -66 11.650* 13.14 Profit of 867 on sale
2025-03-14 SELL -198 11.870* 13.20 Profit of 2,613 on sale
2025-03-13 SELL -66 11.950* 13.22 Profit of 872 on sale
2025-03-12 SELL -1,122 12.310* 13.23 Profit of 14,843 on sale
2025-03-07 SELL -66 10.850* 13.33 Profit of 880 on sale
2025-03-06 SELL -99 10.790* 13.36 Profit of 1,323 on sale
2025-03-03 SELL -33 10.180* 13.50 Profit of 445 on sale
2025-02-28 SELL -198 10.480* 13.55 Profit of 2,683 on sale
2025-02-26 SELL -33 10.230* 13.66 Profit of 451 on sale
2025-02-25 SELL -99 10.560* 13.71 Profit of 1,357 on sale
2025-02-18 BUY 165 11.770* 13.95
2025-02-13 BUY 33 11.920* 14.07
2025-02-12 BUY 33 11.630* 14.12
2025-02-11 BUY 99 11.550* 14.17
2025-02-06 BUY 297 12.800* 14.31
2025-01-27 BUY 33 14.450* 14.47
2024-12-30 BUY 165 10.620* 14.73
2024-12-06 BUY 132 14.020* 14.86
2024-12-05 BUY 33 14.000* 14.89
2024-12-04 BUY 165 14.420* 14.90
2024-11-29 BUY 165 14.510* 15.03
2024-11-27 BUY 132 14.530* 15.08
2024-11-26 BUY 33 14.370* 15.11
2024-11-21 BUY 165 13.380* 15.33
2024-11-20 BUY 99 13.550* 15.43
2024-11-18 BUY 396 13.780* 15.64
2024-11-12 BUY 264 16.610* 15.57
2024-11-08 BUY 165 17.040* 15.47
2024-11-07 BUY 495 16.140* 15.41
2024-11-06 BUY 66 15.720* 15.39
2024-10-31 BUY 33 14.720* 15.52
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-08-21	SELL	-33	14.870*	14.13 Profit of 466 on sale
2025-07-31	BUY	99	17.680*	14.10
2025-06-30	SELL	-66	17.450*	13.67 Profit of 902 on sale
2025-06-25	SELL	-33	17.260*	13.58 Profit of 448 on sale
2025-06-20	SELL	-66	15.800*	13.52 Profit of 892 on sale
2025-05-23	BUY	33	14.980*	13.32
2025-05-19	SELL	-33	14.260*	13.28 Profit of 438 on sale
2025-05-15	SELL	-99	12.195*	13.29 Profit of 1,316 on sale
2025-05-12	SELL	-33	13.290*	13.30 Profit of 439 on sale
2025-05-09	SELL	-33	13.440*	13.30 Profit of 439 on sale
2025-04-30	SELL	-33	13.970*	13.25 Profit of 437 on sale
2025-04-24	SELL	-66	14.640*	13.22 Profit of 872 on sale
2025-04-17	SELL	-33	14.880*	13.14 Profit of 434 on sale
2025-04-15	SELL	-99	14.990*	13.10 Profit of 1,297 on sale
2025-04-14	SELL	-99	14.470*	13.09 Profit of 1,296 on sale
2025-04-09	SELL	-132	13.340*	13.07 Profit of 1,725 on sale
2025-04-07	SELL	-231	12.830*	13.08 Profit of 3,022 on sale
2025-04-04	SELL	-330	12.800*	13.09 Profit of 4,318 on sale
2025-03-31	BUY	33	12.580*	13.10
2025-03-19	SELL	-66	11.650*	13.14 Profit of 867 on sale
2025-03-14	SELL	-198	11.870*	13.20 Profit of 2,613 on sale
2025-03-13	SELL	-66	11.950*	13.22 Profit of 872 on sale
2025-03-12	SELL	-1,122	12.310*	13.23 Profit of 14,843 on sale
2025-03-07	SELL	-66	10.850*	13.33 Profit of 880 on sale
2025-03-06	SELL	-99	10.790*	13.36 Profit of 1,323 on sale
2025-03-03	SELL	-33	10.180*	13.50 Profit of 445 on sale
2025-02-28	SELL	-198	10.480*	13.55 Profit of 2,683 on sale
2025-02-26	SELL	-33	10.230*	13.66 Profit of 451 on sale
2025-02-25	SELL	-99	10.560*	13.71 Profit of 1,357 on sale
2025-02-18	BUY	165	11.770*	13.95
2025-02-13	BUY	33	11.920*	14.07
2025-02-12	BUY	33	11.630*	14.12
2025-02-11	BUY	99	11.550*	14.17
2025-02-06	BUY	297	12.800*	14.31
2025-01-27	BUY	33	14.450*	14.47
2024-12-30	BUY	165	10.620*	14.73
2024-12-06	BUY	132	14.020*	14.86
2024-12-05	BUY	33	14.000*	14.89
2024-12-04	BUY	165	14.420*	14.90
2024-11-29	BUY	165	14.510*	15.03
2024-11-27	BUY	132	14.530*	15.08
2024-11-26	BUY	33	14.370*	15.11
2024-11-21	BUY	165	13.380*	15.33
2024-11-20	BUY	99	13.550*	15.43
2024-11-18	BUY	396	13.780*	15.64
2024-11-12	BUY	264	16.610*	15.57
2024-11-08	BUY	165	17.040*	15.47
2024-11-07	BUY	495	16.140*	15.41
2024-11-06	BUY	66	15.720*	15.39
2024-10-31	BUY	33	14.720*	15.52

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SPRY

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	1,036,811	2,339	1,919,450	54.0%
2025-09-18	517,150	2,816	987,030	52.4%
2025-09-17	379,115	0	772,889	49.1%
2025-09-16	623,491	3,700	1,009,540	61.8%
2025-09-15	663,271	2,900	1,595,652	41.6%
2025-09-12	577,300	0	1,228,781	47.0%
2025-09-11	685,503	145,273	1,124,464	61.0%
2025-09-10	556,371	0	984,013	56.5%
2025-09-09	453,162	0	963,620	47.0%
2025-09-08	859,020	224,358	2,428,498	35.4%
2025-09-05	832,450	76,200	2,588,108	32.2%
2025-09-04	957,847	22,360	2,125,953	45.1%
2025-09-03	766,348	0	2,155,073	35.6%
2025-09-02	861,442	11,887	2,040,774	42.2%
2025-08-29	1,336,171	183,205	3,462,653	38.6%
2025-08-28	547,909	1,125	1,082,195	50.6%
2025-08-27	412,301	500	704,469	58.5%
2025-08-26	553,146	2,580	775,647	71.3%
2025-08-25	615,803	0	1,289,829	47.7%
2025-08-22	1,207,260	601	1,546,063	78.1%
2025-08-21	468,222	50,536	608,426	77.0%
2025-08-20	671,679	26,441	1,106,645	60.7%
2025-08-19	623,980	8,735	1,160,286	53.8%
2025-08-18	382,356	1,900	673,955	56.7%
2025-08-15	844,074	725	1,153,241	73.2%
2025-08-14	1,133,778	22,500	1,427,337	79.4%
2025-08-13	1,127,522	39,066	1,770,071	63.7%
2025-08-12	787,913	0	995,285	79.2%
2025-08-11	351,430	640	901,141	39.0%
2025-08-08	132,685	0	238,497	55.6%
2025-08-07	164,593	9,579	265,414	62.0%
2025-08-06	240,878	103	378,523	63.6%
2025-08-05	192,066	0	313,299	61.3%
2025-08-04	293,472	9,962	499,573	58.7%
2025-08-01	429,256	0	556,082	77.2%
2025-07-31	291,624	0	421,552	69.2%
2025-07-30	232,315	0	483,325	48.1%
2025-07-29	172,573	430	276,477	62.4%
2025-07-28	529,668	0	1,110,316	47.7%
2025-07-25	643,378	0	1,004,276	64.1%
2025-07-24	275,442	0	656,207	42.0%
2025-07-23	235,466	0	569,671	41.3%
2025-07-22	197,912	0	274,374	72.1%
2025-07-21	184,000	0	266,530	69.0%
2025-07-18	349,976	0	556,771	62.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE